Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.
HanchorBio’s HCB301 is among the latest industry projects beginning first-in-human trials.
Two years after being snubbed by GSK, Ideaya shows the promise of MAT2A inhibition.
The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.
Skyscraper-06 blows up spectacularly, and that’s bad news for Skyscraper-01.
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
